![]() ![]() Amarin continues to actively monitor key performance indicators in the U.S. commercial operations continue to support investments in Europe and to expand into new markets. Remained on track to receive reimbursement decisions in up to eight countries with plans to launch VAZKEPA in up to six European countries this year. Received a positive reimbursement assessment from Haute Autorité de Santé (HAS) - the French National Authority for Health – and we have initiated the price negotiation process in that country.Īdvanced continued partnership discussions in Greece, a key market in the region, despite discussions in Central and Eastern Europe being impacted by local political conditions. This is the first of five rounds of price negotiations, while we continue to receive temporary reimbursement for VAZKEPA in the meantime. Initiated the first of several rounds of price negotiations in Germany. Ongoing work underway with the United Kingdom’s National Institute for Health and Care Excellence (NICE), where Amarin received a second Appraisal Consultation Document (ACD). We remain focused on accomplishing the objectives we set for 2022 and look forward to making significant progress throughout the balance of this year and beyond.”Īchieved the first national reimbursement decision for VAZKEPA in Sweden, which marks the beginning of the next phase of the company’s growth and expansion effort outside of the U.S.Ĭlinical and Health Technology Assessment processes and reimbursement discussions are progressing across all of the targeted markets in Europe where Amarin has submitted market access dossiers, including Norway, Finland, Germany, the United Kingdom (UK), France, Italy, Spain, Denmark and the Netherlands, and have: go-to-market strategy and made progress on our fixed-dose combination portfolio. “In summary, during the first quarter, we made meaningful advances toward achieving greater geographic reach for VASCEPA ®/VAZKEPA in key markets, advanced our U.S. We also remain committed to operational excellence where we enhanced our leadership team with the right talent to support the company’s next steps as we execute against a BOLD vision to stop heart disease from being the leading cause of death, worldwide.” In parallel, we are accelerating our efforts toward greater diversification as we advance the development of our fixed-dose combination of VASCEPA with a statin. ![]() This includes the PRIOR-MI sub-analysis recently published in the Journal of the American College of Cardiology. “We are also focused on maximizing the value of VASCEPA/VAZKEPA and continue to benefit from the REDUCE-IT study, which continues to produce compelling and impactful analyses of this landmark outcomes trial. Our global expansion strategy is continuing to take shape, with additional regulatory filings completed in several key geographies and active partnership discussions underway in specific countries.” Looking ahead, we continue to advance reimbursement discussions in multiple markets and have initial launch activities underway as we remain on track to deliver on our commitment to obtain reimbursement status and launch in up to six key European markets this year. This reimbursement acknowledges the value VAZKEPA provides to cardiovascular care. In Europe, we received the first national reimbursement for VAZKEPA in Sweden, which marked the first step in the next phase of our geographic expansion strategy. “In the U.S., we are continuing to execute on our go-to-market strategy to help drive VASCEPA revenue with this focused approach, while also maintaining our focus on profitability and contribution margin. as we faced a third generic entrant to the market during the quarter,” said Karim Mikhail, president and chief executive officer of Amarin. “In the first quarter of 2022, we made important progress across all three pillars of our long-term growth strategy while working through the impact to VASCEPA in the U.S. ETĭUBLIN, Ireland and BRIDGEWATER, N.J., (GLOBE NEWSWIRE) - Amarin Corporation plc (NASDAQ:AMRN), today announced financial results for the quarter ended Maand provided an update on company operations. Plans for Regulatory Filings for Approval of VASCEPA ® (icosapent ethyl) in Several Additional Countries in 2022Ĭompany to Host Conference Call Today at 8:00 a.m. Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European MarketsĬontinued Progress on Go-To-Market Strategy in the US Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |